Journal: Nature Communications
Article Title: Human protein interaction networks of ancestral and variant SARS-CoV-2 in organ-specific cells and bodily fluids
doi: 10.1038/s41467-025-60949-1
Figure Lengend Snippet: a SARS-CoV-2 S protein structure shows domains and InSiPS-derived peptides (arrows) targeting the receptor-binding domain (RBD) and S1/S2 protease cleavage site. SS, single sequence; NTD, N-terminal domain; SD1, subdomain 1; SD2, subdomain 2; S2’ (black arrow), protease cleavage site; FP, fusion peptide; HR1, heptad repeat 1; CH, central helix; CD, connector domain; HR2, heptad repeat 2; TM, transmembrane domain; CT, cytoplasmic tail. b qRT-PCR of viral RNA in Huh-7 cells treated with SARS-CoV-2 and RBD-binding antiviral peptides (AVPs) at specified concentrations were compared to virus-only or vehicle (DMSO) controls (data are mean ± SEM ( n = 3–13 biological samples; P = 8.3e −5 ≤ P ≥ 2.7e −2 or P ≤ 1.1e −4 by one or two-sided, paired or unpaired t -test). c mRNA expression of markers in SARS-CoV-2-infected Huh-7-ACE2 cells treated with AVPs measured by qRT-PCR and compared to untreated controls ( n = 3 biological replicates; 6.7e −8 ≤ P ≥ 2.0e −4 by two-sided, paired t -test). d Plaque assays in Vero E6 - TMPRSS2 cells show dose-dependent AVP inhibition of ancestral and variant SARS-CoV-2 ( n = 2 biological replicates per dose). e Surface plasmon resonance (SPR, right) shows ACE2 (positive control) or AVP binding to His-tagged S-RBD (wild-type, Delta with T478K L452R mutations, and Omicron with 16 mutations). SPR (left) reveals AVPs inhibit ACE2 binding to wild-type or mutated S-RBD. f SEC-HPLC/MS-based hierarchical clustering of co-fractionated protein profiles in SARS-CoV-2-infected Huh-7 cells treated with AVPs vs. mock (uninfected/untreated) control. g Heatmap shows AVP-treated SARS-CoV-2-infected Huh-7 cells exhibit protein coelution profiles more similar to mock (uninfected/untreated) control than to untreated virus-infected cells. h Viral-host protein pairs ( n = 48) show altered correlations in AVP-treated SARS-CoV-2-infected Huh-7 cells, but not in those treated with AVP 1 or AVP 2 (PCC < 0.25). PCC differences for each co-eluted human protein pair were calculated across samples, with two-sided Z-transformed P -values adjusted for FDR ≤ 5e −2 using the BH method. Source data are provided as a Source Data file.
Article Snippet: Full-length human ACE2 with C-terminal Myc and FLAG tags in pCMV6-entry vector (Origene RC208442) was expressed in Expi293 cells and purified as described previously .
Techniques: Derivative Assay, Binding Assay, Sequencing, Quantitative RT-PCR, Virus, Expressing, Infection, Inhibition, Variant Assay, SPR Assay, Positive Control, Control, Transformation Assay